MedPath

Allopurinol

Generic Name
Allopurinol
Brand Names
Aloprim, Zyloprim
Drug Type
Small Molecule
Chemical Formula
C5H4N4O
CAS Number
315-30-0
Unique Ingredient Identifier
63CZ7GJN5I
Background

Gout is a disease that occurs by the deposition of monosodium urate crystals (MSU) in body tissues, especially around joints . This disease has been well-documented in historical medical records and appears in the biographies of several prominent, historically recognized individuals .

Allopurinol is a xanthine oxidase enzyme inhibitor that is considered to be one of the most effective drugs used to decrease urate levels and is frequently used in the treatment of chronic gout . It was initially approved by the FDA in 1966 and is now formulated by several manufacturers .

Indication

Allopurinol is indicated in :

1) the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy).

2) the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment with allopurinol should be discontinued when the potential for overproduction of uric acid is no longer present.

3) the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. Therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks.

Associated Conditions
Hyperuricemia, Primary Gout, Recurrent calcium oxalate calculi, Secondary gout, Calcium oxalate calculi Renal Calculi
Associated Therapies
-

Uric Acid Reduction as a Novel Treatment for Pediatric Chronic Kidney Disease

Phase 2
Terminated
Conditions
Chronic Kidney Diseases
Hyperuricemia
Interventions
First Posted Date
2019-03-06
Last Posted Date
2021-05-27
Lead Sponsor
Virginia Commonwealth University
Target Recruit Count
17
Registration Number
NCT03865407
Locations
🇺🇸

Virginia Commonwealth University, Richmond, Virginia, United States

A Study to Assess the Safety and Pharmacokinetics of Verinurad and Allopurinol in Asian and Chinese Subjects

Phase 1
Completed
Conditions
Chronic Kidney Disease
Interventions
First Posted Date
2019-02-11
Last Posted Date
2019-05-13
Lead Sponsor
AstraZeneca
Target Recruit Count
6
Registration Number
NCT03836599
Locations
🇺🇸

Research Site, Glendale, California, United States

Evaluation of a Treatment With Allopurinol in Adenylosuccinate Lyase Deficiency

Phase 2
Completed
Conditions
Adenylosuccinate Lyase Deficiency
Interventions
First Posted Date
2018-12-17
Last Posted Date
2022-10-12
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
8
Registration Number
NCT03776656
Locations
🇫🇷

Department of Pediatry. Reference centre of Hereditary diseases of the metabolism of child and adult. Necker - Enfants malades Hospital, Paris, France

🇫🇷

LA PITIE-SALPETRIERE Hospital, AP-HP, Paris, France

Effect of Allopurinol or Febuxostat to Prevent Contrast Induced Acute Kidney Injury (CI-AKI)

Phase 2
Conditions
Contrast-induced Nephropathy
Contrast-induced Acute Kidney Injury
Interventions
First Posted Date
2018-12-06
Last Posted Date
2018-12-06
Lead Sponsor
Instituto Nacional de Cardiologia Ignacio Chavez
Target Recruit Count
558
Registration Number
NCT03767322
Locations
🇲🇽

Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, México City, Mexico

Allopurinol in Diabetes Mellitus and Multivessel Coronary Artery Disease

Phase 4
Conditions
Multi Vessel Coronary Artery Disease
Diabetes Mellitus
Ischemic Heart Disease
Interventions
First Posted Date
2018-10-09
Last Posted Date
2018-11-21
Lead Sponsor
Tel-Aviv Sourasky Medical Center
Target Recruit Count
100
Registration Number
NCT03700645

The Effect of Antioxidants on Skin Blood Flow During Local Heating

Phase 1
Completed
Conditions
Cardiovascular Diseases
Vasodilation
Cardiovascular Risk Factor
Interventions
Drug: Apocynin
Drug: Allopurinol
Other: Control (Lactated Ringer's)
Drug: Tempol
First Posted Date
2018-09-21
Last Posted Date
2018-09-21
Lead Sponsor
The University of Texas at Arlington
Target Recruit Count
44
Registration Number
NCT03680638
Locations
🇺🇸

Engineering Research Building, Arlington, Texas, United States

The Effect of Antioxidants on Skin Blood Flow-BH4

Phase 1
Completed
Conditions
Cardiovascular Diseases
Cardiovascular Risk Factor
Vasoconstriction
Interventions
First Posted Date
2018-09-21
Last Posted Date
2018-09-26
Lead Sponsor
The University of Texas at Arlington
Target Recruit Count
16
Registration Number
NCT03680573
Locations
🇺🇸

Engineering Research Building, Arlington, Texas, United States

Sex-related Differences in Arterial Stiffness in Type 2 Diabetics: Role of Uric Acid

Phase 2
Completed
Conditions
Hyperuricemia
Diabetes Mellitus, Type 2
Interventions
Drug: Placebo
Other: Low-fructose diet, isocaloric
Other: Low-fructose, hypocaloric
Drug: Allopurinol
First Posted Date
2018-08-28
Last Posted Date
2023-07-03
Lead Sponsor
University of Missouri-Columbia
Target Recruit Count
34
Registration Number
NCT03648996
Locations
🇺🇸

University of Missouri, Columbia, Missouri, United States

The Percentage of Cases of Acute Treatment With Allopurinol in Gout Patients

Not Applicable
Conditions
Gout
Interventions
First Posted Date
2018-07-26
Last Posted Date
2018-07-26
Lead Sponsor
Hillel Yaffe Medical Center
Target Recruit Count
700
Registration Number
NCT03601260
Locations
🇮🇱

Hillel Yaffe Medical Center, Hadera, Israel

A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion

Phase 2
Recruiting
Conditions
Multiple Myeloma
Interventions
First Posted Date
2018-06-27
Last Posted Date
2022-06-22
Lead Sponsor
Swedish Medical Center
Target Recruit Count
100
Registration Number
NCT03570983
Locations
🇺🇸

Swedish Cancer Institute, Seattle, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath